Life sciences real estate sits at the intersection of two demanding disciplines: institutional property ownership and deep fluency in the biology, chemistry, and regulatory frameworks that govern your tenants’ work. For real estate CEOs who have built or are building meaningful positions in wet labs, GMP manufacturing, and research campuses, the time allocation challenge is unlike anything in multifamily, office, or industrial. Your tenants are running clinical trials. Their space requirements shift when a drug candidate clears Phase II. A single lease expiration can hollow out an entire campus. Getting your attention architecture right is not a preference; it is an operating imperative.
This article lays out how leading real estate CEOs structure their time and bandwidth when life sciences assets represent a significant portion of their portfolio.
Why Life Sciences Demands a Different Time Model
Most commercial real estate categories allow a CEO to operate at a reasonable remove from the property level. You set strategy, manage capital, oversee your leadership team, and engage selectively with major tenants. Life sciences collapses that distance. The technical complexity of the product, the concentration of tenant risk, and the tight relationship between your deal flow and the venture capital ecosystem all require sustained personal engagement that you cannot fully delegate.
The sector also moves on a different clock. A biotech company can go from Series B to needing 80,000 square feet of BSL-2 lab space in 18 months, then face a pipeline setback and need to sublease half of it. Staying ahead of those inflection points requires genuine proximity to the tenants and to the investors funding them.
The Concentration Risk Problem
Unlike a diversified office or industrial portfolio, a single life sciences tenant can represent 30 to 50 percent of a building’s revenue. A 200,000-square-foot research campus with two anchor tenants is not unusual. That concentration means your tenant relationships are not account management; they are enterprise risk management. Your personal involvement in those relationships is not optional.
How to Allocate Your Time Across the Core Demands
Tenant Relationships with Biotech and Pharma Companies
This is where most life sciences real estate CEOs underinvest relative to what the asset class requires. Your institutional biotech and pharma tenants have sophisticated real estate teams, but the relationships that matter are the ones you hold directly with their C-suite counterparts. The head of facilities, the CFO, the VP of research operations: these are the people who shape space decisions 18 to 36 months before a lease event surfaces in your pipeline.
Allocate structured time quarterly to meet with the senior leadership of your top five to ten tenants. These are not courtesy calls. You are gathering intelligence on their pipeline progress, hiring plans, and capital position. A tenant that raised a strong Series C and is adding 40 scientists in the next year is a tenant who may need expansion space. A tenant whose lead asset just failed in Phase III is a tenant whose renewal probability just dropped materially.
Build a cadence that includes formal quarterly business reviews with your largest tenants and informal touchpoints (industry conferences, campus events, shared ecosystem gatherings) in between. Your asset management team owns the operational relationship; you own the strategic one.
Technical Construction and Fit-Out Oversight
Wet lab construction is among the most technically demanding and cost-intensive work in commercial real estate. A standard lab-ready shell requires HVAC systems capable of 100 percent outside air, vibration-isolated slabs, specialized exhaust and plumbing infrastructure, and electrical capacity that dwarfs conventional office. GMP manufacturing space adds cleanroom classification, validated HVAC systems, and regulatory documentation requirements that intersect directly with FDA compliance.
As CEO, you do not need to be the technical expert. But you do need to understand the decisions well enough to govern them. That means spending time with your development and construction leadership on a rhythm that keeps you informed about cost trends, schedule risks, and the technical trade-offs being made on active projects.
The specific area where your involvement pays the highest dividend is in the earliest design decisions. Choices made in schematic design about floor-to-floor heights, structural loading, and mechanical shaft placement shape the flexibility and residual value of the asset for decades. Getting in front of those decisions, even briefly, is worth considerably more than reviewing change orders after the fact.
Set a standing monthly review with your head of development that covers active construction projects, upcoming fit-out commitments, and any material deviations from underwriting. Ask the questions that keep your team sharp: What is the cost to convert this space from BSL-2 to BSL-3 if we need to? What is the lead time on the HVAC equipment? If this tenant delays their fit-out start by 90 days, what does that do to our delivery schedule and our draw schedule?
Proximity to the Venture Capital Ecosystem
In the major life sciences clusters (Greater Boston, the San Francisco Bay Area, San Diego, the Research Triangle), the venture capital community and the real estate community are more interdependent than in virtually any other sector. VC firms are often the direct or indirect decision-makers on where their portfolio companies locate. The ability to be known and trusted in that community is a genuine competitive advantage for a life sciences real estate CEO.
This is not about sponsoring events or showing up at pitch competitions. It is about building genuine relationships with the partners at life sciences-focused VC firms who are actively deploying capital. When a partner at a top-tier fund knows that you can deliver 40,000 square feet of lab-ready space with tenant improvement flexibility and a team that understands a startup’s cash constraints, your property gets shown first.
Allocate meaningful time, perhaps 10 to 15 percent of your external-facing hours, to the VC and incubator ecosystem. Serve on advisory boards where appropriate. Host events at your campuses. Be present at the key industry conferences where capital and science intersect: BIO, J.P. Morgan Healthcare Conference, and the regional cluster-specific events that attract early-stage companies.
Your capital raising strategy for life sciences assets will benefit directly from these VC relationships, since many life sciences-focused funds have real estate or infrastructure arms that co-invest with operating platforms.
Managing Long Tenant Dependency Risk
The single most distinctive risk in life sciences real estate is what happens when a major tenant’s science fails. Unlike an office tenant whose business declines gradually, a biotech company can go from healthy to existential in the time it takes a clinical trial to read out. Your role as CEO is to ensure the organization is managing that risk actively, not reactively.
This means building a tenant health monitoring practice that goes beyond rent collection. Track your tenants’ capital positions (many are public or have disclosed funding rounds), their clinical pipeline milestones, and their headcount trends. Establish early warning indicators that trigger proactive outreach: a tenant that stops growing, a tenant that has missed two consecutive hiring milestones, or a tenant whose last funding round was more than 18 months ago in a market where 12-month runways are common.
When warning signs appear, the CEO’s role is to get in the room early. A tenant facing financial pressure is far more likely to reach a workable solution (structured sublease, lease modification, phased space reduction) if your organization is a trusted partner rather than a landlord showing up with default notices.
Diversification is the structural answer to concentration risk. Your deal pipeline management should include explicit targets for tenant size distribution, stage of company, and therapeutic focus area so that no single tenant event can materially impair a campus’s performance.
The Ecosystem and Partnership Dimension
Life sciences real estate at scale is an ecosystem business. The most valuable campuses are not just buildings; they are communities where the proximity of companies, shared amenity infrastructure, and programmatic events create genuine value for tenants that pure real estate cannot replicate.
Building Institutional Relationships with Universities and Research Hospitals
Many of the best life sciences campuses are anchored by or adjacent to major academic medical centers or research universities. These relationships require CEO-level stewardship. The president’s office, the technology transfer office, and the research administration teams at major institutions are not relationships that can be managed at the asset management level. They require your personal engagement because the stakes are high: a strategic partnership with a major AMC can generate a sustained pipeline of spinout companies, research collaborations, and anchor tenants that is extremely difficult to replicate.
Allocate time annually to deepen one or two of these institutional relationships. That might mean joining an advisory board, co-hosting a symposium, or funding a fellowship program. The returns are long-term and relationship-dependent, which is exactly why your personal time carries more weight than any amount of transactional outreach.
Government and Economic Development Engagement
Life sciences clusters depend on public investment in infrastructure, workforce development, and research funding. State and local economic development agencies are often significant influencers in where institutional research capacity grows. A CEO who is engaged with these stakeholders has access to information and influence that shapes the long-term trajectory of the markets you operate in.
This is not a lobbying function. It is a genuine community investment that happens to generate strategic intelligence and relationship capital. According to JLL’s Life Sciences Outlook, cluster dynamics and public investment in research infrastructure are among the top drivers of long-term life sciences real estate demand. Your engagement with that ecosystem is part of how you protect and grow the value of your assets.
Time Architecture for the Life Sciences CEO
The practical question is how to structure a week and a quarter so that all of these demands get appropriate attention without turning the CEO role into a triage function.
Weekly Rhythm
Protect time for strategic thinking and relationship work. The operational demands of life sciences real estate, the construction reviews, the tenant escalations, the capital markets activity, will always expand to fill available time if you let them. The disciplines that create long-term value (ecosystem relationships, portfolio strategy, scenario planning for tenant risk) require protected, uninterrupted blocks.
A reasonable weekly architecture dedicates mornings to strategic work and preserves afternoons for operational reviews and external meetings. Your executive assistant plays a critical role in enforcing this architecture, particularly in filtering which tenant escalations actually require your involvement versus which are better handled by your asset management team.
Quarterly Priorities
Each quarter should have a defined set of strategic priorities that get explicit calendar time: the two or three tenant relationships that most need CEO attention, the capital or development decisions that are at an inflection point, and the ecosystem investments (VC relationships, institutional partnerships, government engagement) that require consistent presence over time.
Life sciences real estate rewards patience and depth. The CEOs who have built the most durable platforms in this sector are those who have invested in relationships and ecosystem positioning over years, not quarters. Your time allocation is the primary mechanism through which that investment is made.
The Talent and Team Dimension
No CEO can personally cover all of the technical and relationship demands of a serious life sciences platform. Building a team with genuine sector expertise is as important as your own time allocation.
Your head of leasing needs to understand biotech business models. Your head of development needs deep experience in lab and GMP construction. Your asset management leads need to be capable of sophisticated tenant health monitoring. When your team has these capabilities, your time can be spent on the highest-leverage activities: the relationships and decisions that genuinely require the CEO.
Invest time in the development of these team members. Bring them into key external relationships. Give them visibility at industry events. The depth of your team is a competitive moat in a sector where genuine expertise is genuinely scarce.
Conclusion
Life sciences real estate is among the most intellectually demanding and operationally complex categories in commercial real estate. For CEOs building meaningful positions in this sector, the time allocation challenge is real and consequential. Getting it right means building genuine ecosystem relationships with the venture and academic communities that drive demand, maintaining close oversight of technically complex construction and fit-out, actively managing the concentration risks inherent in the tenant base, and doing all of this while maintaining the strategic clarity and capital discipline that any large real estate platform requires.
The CEOs who lead the strongest life sciences platforms share a common characteristic: they are genuinely curious about the science. Not at the level of a researcher, but at the level of someone who understands why a tenant’s space requirements are what they are, who can have an informed conversation about a drug development program, and who is recognized by the biotech community as a real partner rather than a passive landlord. That posture shapes everything from how you allocate your time to how your organization is perceived in the markets where you compete.